2018 FIGO子宫颈癌分期系统:引入横断面成像
2018年国际妇产科联盟(FIGO)子宫颈癌分期系统将影像学置于核心地位,要求更精确地测量原发肿瘤大小(最好通过影像学评估),并将腹盆腔腹膜后淋巴结病变评估(影像学或病理学分析)纳入分期。检查方式的选择取决于执业环境中可用的技术:高资源环境使用盆腔MRI和躯干氟脱氧葡萄糖PET/CT,低资源环境使用盆腔超声和胸部X线摄影。
要点
- 2018 FIGO分期要求更精确测量原发肿瘤大小,最好通过影像学评估。
- 腹盆腔腹膜后淋巴结病变评估(影像学或病理学)现已纳入分期。
- 高资源环境用盆腔MRI评估肿瘤大小和盆腔中央扩散,用躯干FDG PET/CT评估淋巴结和远处转移。
核心结论
- 影像学在2018 FIGO子宫颈癌分期系统中起核心作用,将影像学纳入分期指派是新进展。
研究设计与样本
- 本文为对2018 FIGO子宫颈癌分期系统的解读,说明影像学在分期中的应用;未报告研究设计、样本量或中心数。
临床应用与阅片要点
- 高资源环境使用盆腔MRI评估肿瘤大小和盆腔中央扩散,使用躯干氟脱氧葡萄糖PET/CT评估淋巴结病变和远处转移,以指派分期并制定治疗计划;低资源环境使用盆腔超声和胸部X线摄影作为类似检查方式。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Imaging plays a central role in the 2018 International Federation of Gynecology and Obstetrics staging system for uterine cervical cancer. The revision calls for a more precise measurement of primary tumor size, best assessed with imaging. Evaluation for abdominopelvic retroperitoneal lymphadenopathy, either with imaging alone or with pathologic analysis, is now also part of staging. Choice of modality depends on the technology available within the practice setting. In high-resource settings, pelvic MRI (to assess tumor size and central pelvic spread) and torso fluorodeoxyglucose PET/CT (to assess lymphadenopathy and distant metastases) are used to assign stage and to plan therapy. In lower-resource settings, analogous modalities are pelvic US and chest radiography. Although imaging is already a part of pretreatment planning in some high-resource settings, its incorporation into assigning stage is a new development.
引用
- Lee SI, Atri M. 2018 FIGO Staging System for Uterine Cervical Cancer: Enter Cross-sectional Imaging. Radiology. 2019. PMID: 31135294. doi:10.1148/radiol.2019190088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。